Xeris Biopharma Holdings shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $5.
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma Holdings' stock price increased following Oppenheimer's initiation of coverage with an Outperform rating and a price target of $5.
March 28, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xeris Biopharma Holdings' stock price is likely to experience a short-term increase following the positive analyst coverage from Oppenheimer, which includes an Outperform rating and a $5 price target.
Analyst ratings, especially from reputable firms like Oppenheimer, can significantly influence investor sentiment and stock prices. The Outperform rating and the $5 price target suggest a strong bullish outlook for Xeris Biopharma Holdings, likely leading to increased investor interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100